Clinical Study Of Affinity Versus SOC In The Management Of VLUs

NCT ID: NCT04901013

Last Updated: 2021-09-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-14
• Study Completion Date: 2023-06-30

Brief Summary

This prospective, multi-center, randomized, controlled clinical study compares Affinity® plus SOC to SOC alone in subjects with VLUs. Affinity® will be used along with standard of care on venous leg ulcers (VLUs) of greater than 4 weeks which have not adequately responded to conventional ulcer therapy.

Detailed Description

Two hundred (200) subjects with a chronic VLU ranging in size from 2cm2 and 80 cm2 will be randomized 1:1 to either Affinity® and SOC or SOC alone following the 28 day screening period. Following screening and randomization, subjects shall be seen weekly for up to 24 weeks. For subjects that heal prior to week 24, a healing confirmation visit shall occur two weeks later to confirm maintenance of complete wound closure.

Subjects that are randomized into the SOC group whose VLU has not healed by week 12 may be crossed over to receive Affinity® and followed for an additional 12-14 weeks.

Conditions

Venous Leg Ulcer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Affinity plus SOC

Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM). Affinity is human allograft tissue that is regulated as a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) as defined by FDA 21 CFR Part 1271. Affinity may be applied as a wound covering to partial- and full-thickness acute and chronic wounds

Group Type: ACTIVE_COMPARATOR

Affinity

Intervention Type: OTHER

Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM).

Standard of Care (SOC)

Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Affinity

Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM).

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Ulcers of venous origin, as clinically determined by clinical signs and symptoms (e.g. hyperpigmentation of the surrounding skin, history of swelling, varicosities, lipodermatosclerosis and/or dermatitis) or other assessments (e.g. venous reflux test).

2. Venous insufficiency ulcers, of at least 1-month duration, which have not adequately responded to conventional ulcer therapy

3. Venous insufficiency ulcers between 2 cm2 and 80 cm2

4. Partial- or full-thickness VLU, including ulcers with tissue damage that extends through the epidermis and into the upper epidermis (papillary dermis), or into the deep dermis (reticular dermis) but not through muscle, tendon, capsule, or into bone.

5. Subjects are between 18 and 85 years of age.

6. IRB approved Informed Consent Form is signed before screening and treatment.

7. Subject is expected to be available for 24 week follow-up

8. Females of child-bearing potential must be practicing an acceptable means of birth control as determined by the investigator.

9. Subjects with bilateral ulcers may be enrolled.

Exclusion Criteria

1. Ankle Brachial Index (ABI) of <0.65

2. Venous insufficiency ulcers less than 2cm2 or greater than 80cm2

3. Vasculitis, severe rheumatoid arthritis, and other collagen vascular diseases

4. Clinically significant medical conditions which would impair wound healing, as determined by the investigator, including renal, hepatic, hematologic, neurologic or immune disease

5. Signs and symptoms of infection, cellulitis, osteomyelitis

6. Necrotic or avascular ulcer beds

7. Ulcer with exposed bone, tendon or fascia

8. Subjects receiving hemodialysis or have uncontrolled diabetes

9. Subjects who are currently receiving or have received at any time within one month prior to entry into the study, corticosteroids (>15 mg/day), immunosuppressive agents, radiation therapy, or chemotherapy. Anticipated use of the above agents will exclude subjects from entry into the study.

10. Subjects enrolled in other wound drug investigational studies within the past three months, or device studies within the past 30 days.

11. Subject is pregnant or breast feeding.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Organogenesis

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Christine McLennan

Role: STUDY_DIRECTOR

Organogenesis Inc.

Locations

ILD Research

Carlsbad, California, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Galen Hale

Role: CONTACT

GHale@organo.com

(205) 541-9682

Andrea Black

Role: CONTACT

ABlack@organo.com

(781) 830-2364

Facility Contacts

Eric Martinez

Role: primary

eric@ildresearch.com

Other Identifiers

20-VLU-003-AFF

Identifier Type: -

Identifier Source: org_study_id